Immunitybio announces $470 million equity and debt financing from founder, dr. patrick soon-shiong and nant entities

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced that it has executed financing transactions resulting in approximately $200 million of proceeds to the company through a financing including an exchange into equity of current debt and a new convertible debt instrument from nant capital, llc, an entity affiliated with dr. patrick soon-shiong, the company's founder, executive chairman and global chief scientific and med.
IBRX Ratings Summary
IBRX Quant Ranking